Lisa McGrath
Human Resources Officer at SURFACE ONCOLOGY, INC.
Profile
Lisa McGrath is currently the Chief People Officer at Surface Oncology, Inc. She previously worked as the Director of Human Resources & Administration at BioSphere Medical, Inc. and as the Vice President of Human Resources at Predictive Biosciences, Inc. From 2013 to 2015, she served as the Vice President of Human Resources at Intelligent Medical Devices, Inc. Ms. McGrath completed her undergraduate degree at Notre Dame College (Ohio).
Lisa McGrath active positions
Companies | Position | Start |
---|---|---|
SURFACE ONCOLOGY, INC. | Human Resources Officer | 2017-07-31 |
Former positions of Lisa McGrath
Companies | Position | End |
---|---|---|
Intelligent Medical Devices, Inc.
Intelligent Medical Devices, Inc. Pharmaceuticals: MajorHealth Technology Intelligent Medical Devices, Inc. engages in the designs development and manufacture of platform-agnostic, regulatory-cleared molecular diagnostic tests. The company was founded by Alice A. Jacobs Nesselrodt in 2000 and is headquartered in Waltham, MA. | Human Resources Officer | 2014-12-31 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Chief Administrative Officer | 2009-12-31 |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Human Resources Officer | - |
Training of Lisa McGrath
Notre Dame College (Ohio) | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Health Technology |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
Intelligent Medical Devices, Inc.
Intelligent Medical Devices, Inc. Pharmaceuticals: MajorHealth Technology Intelligent Medical Devices, Inc. engages in the designs development and manufacture of platform-agnostic, regulatory-cleared molecular diagnostic tests. The company was founded by Alice A. Jacobs Nesselrodt in 2000 and is headquartered in Waltham, MA. | Health Technology |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Lisa McGrath